Furthermore, while cytokines such as interleukin-6 (IL-6) have been linked to stroke severity and outcomes (26), they are less accessible in routine clinical settings due to higher cost, longer turnaround time, and variability in measurement techniques. This evidence concerns the gene IL6 and stroke disorder.